CELLPOINT
CellPoint is dedicated to developing CAR-T therapies at the point of care, making these therapies more affordable and accessible to patients. CellPoint has developed a 6-day manufacturing process, powered by its proprietary xCellit real-time monitoring software system, that allows for 1 week of vein-to-vein time compared to over one month with current industrial manufacturing platforms.
CELLPOINT
Social Links:
Industry:
Biotechnology Health Care
Founded:
2018-01-01
Address:
Oegstgeest, Zuid-Holland, The Netherlands
Country:
The Netherlands
Website Url:
http://www.cellpoint.bio
Total Employee:
1+
Status:
Active
Contact:
+31 712077810
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Font Awesome Apache Wordpress Plugins
Current Advisors List
Official Site Inspections
http://www.cellpoint.bio Semrush global rank: 4.26 M Semrush visits lastest month: 2.73 K
- Host name: server-99-86-229-18.iad79.r.cloudfront.net
- IP address: 99.86.229.18
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "CellPoint"
CellPoint - Galapagos
CellPoint was a biotechnology company founded in 2018 in the Netherlands. They developed a decentralized T-cell manufacturing platform. In 2022 CellPoint was acquired by Galapagos. Since then, they have been united around a …See details»
CellPoint - Crunchbase Company Profile & Funding
CellPoint is dedicated to developing CAR-T therapies at the point of care, making these therapies more affordable and accessible to patients. CellPoint has developed a 6-day manufacturing …See details»
CellPoint - LinkedIn
CellPoint | 4,526 followers on LinkedIn. CellPoint enables clinicians to treat hematological malignancies by retargeting patient immune cells at the point-of-care. In 2022, CellPoint was …See details»
AboundBio & CellPoint acquisition - Galapagos
CellPoint’s CAR-T cell-therapy is of investigational nature and is not approved by the FDA or any other regulatory authority forany use. Its efficacy and safety have not been established. …See details»
Galapagos to acquire CellPoint and AboundBio to accelerate
Jun 21, 2022 More information at www.cellpoint.bio. About AboundBio AboundBio is an innovative privately held biotechnology company whose mission is to generate novel antibody …See details»
Galapagos to acquire CellPoint and AboundBio to advance cell …
Jun 22, 2022 Under the terms of the agreements, Galapagos is to acquire all outstanding shares of CellPoint and AboundBio in an all-cash transaction against payment of an upfront amount of …See details»
Galapagos NV (GLPG) Acquires CellPoint and AboundBio
Jun 21, 2022 More information at www.cellpoint.bio. About AboundBio AboundBio is an innovative privately held biotechnology company whose mission is to generate novel antibody …See details»
Galapagos to acquire CellPoint and AboundBio to accelerate …
Jun 21, 2022 About CellPoint CellPoint is dedicated to developing CAR-T therapies at the point-of-care, making these therapies more affordable and accessible to patients. CellPoint has …See details»
Galapagos to buy CellPoint, AboundBio to boost …
Jun 22, 2022 Galapagos has signed agreements to acquire all outstanding shares of CellPoint and AboundBio to boost access to next-generation cell therapies, in an all-cash deal totalling $251m. Under the definitive agreements …See details»
CellPoint - Company Profile - Tracxn
Nov 16, 2024 CellPoint ranks 199th among 311 active competitors. 122 of its competitors are funded while 76 have exited. Overall, CellPoint and its competitors have raised over $14B in …See details»
Galapagos to acquire CellPoint and AboundBio to …
Jun 22, 2022 Galapagos NV, CellPoint and AboundBio announced that both companies have entered into definitive agreements with Galapagos, propelling Galapagos into next-generation cell therapy while significantly broadening its …See details»
Galapagos to acquire CellPoint and AboundBio to accelerate …
Jun 23, 2022 CellPoint has developed, in a strategic collaboration with Lonza, a novel point-of-care supply model, which offers the potential for efficient, 7-day delivery of CAR-T therapies …See details»
Galapagos, with latest deals, charts an unexpected journey to cell ...
Jun 22, 2022 Galapagos intends to buy Cellpoint through an upfront payment of 125 million euros, or roughly $131 million, with another 100 million euros contingent upon the …See details»
Galapagos to acquire CellPoint and AboundBio to accelerate …
Jun 21, 2022 All cash acquisition of CellPoint for an upfront amount of €125 million, with milestone payments up to €100 million and AboundBio for $14 million Webcast presentation …See details»
Galapagos shifts gears with Cellpoint, Aboundbio acquisitions
Galapagos NV is making a decisive shift away from its small-molecule roots, sealing the simultaneous acquisition of CAR T-cell therapy specialist Cellpoint BV and fully-human …See details»
Galapagos to acquire CellPoint and AboundBio to accelerate …
Jun 21, 2022 All cash acquisition of CellPoint for an upfront amount of €125 million, with milestone payments up to €100 million and AboundBio for $14 million. Webcast presentation …See details»
CellPoint Overview | SignalHire Company Profile
CellPoint enables clinicians to treat hematological malignancies by retargeting patient immune cells at the point-of-care.Get in touch or visit our website: https://cellpoint.bio Organization …See details»
CellPoint and Hypertrust Patient Data Care co-develop xCellit …
Nov 30, 2021 About CellPoint. CellPoint is a Dutch (EU) company founded to provide affordable and readily available CAR-T therapies for all patients in need. The CellPoint CAR-T treatment …See details»
Office manager - cellpoint.bio
CellPoint BV, BioPartner Center, De Limes 7 , 23 42 D H Oegstgeest , The Netherlands www.cellpoint.bio Office manager Oegstgeest , The Netherlands About CellPoint Engineering …See details»
CellPoint: bringing autologous CAR Ts to point of care
Jun 23, 2021 Emerging Company Profile: CellPoint aims to broaden access to CAR Ts with point-of-care manufacturing platform By Virginia Li, Associate Editor June 23, 2021 12:32 PM …See details»